跳到正文
原文
Agios Pharmaceuticals|阿吉欧斯制药· Agios Pharmaceuticals, Inc. News Releases·· 4 小时前重要性评分8

Agios 将于 11 月 5 日 8:00 a.m. ET 召开 2026 年第三季度财报电话会及网络直播

Agios to Host Third Quarter 2026 Financial Results Conference Call and Webcast on November 5 at 8:00 a.m. ET

AI 导读

Agios Pharmaceuticals(Nasdaq: AGIO)宣布将于 2026 年 11 月 5 日(周四)美国东部时间 8:00 a.m. 举行电话会议和网络直播,公布 2026 年第三季度财务业绩及业务进展。直播可在公司官网投资者板块“Events & Presentations”栏目收听,回放将在活动结束后约两小时上线。

正文

CAMBRIDGE, Mass., Oct. 08, 2026 (GLOBE NEWSWIRE) -- Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company focused on delivering innovative medicines for patients with rare diseases, today announced the company will host a conference call and live webcast on Thursday, November 5, 2026, at 8:00 a.m. ET to report its third quarter 2026 financial results and business highlights.

The live webcast will be accessible on the Investors section of the company’s website (www.agios.com) under the “Events & Presentations” tab. A replay of the webcast will be available on the company’s website approximately two hours after the event.

About Agios: Fueled by Connections to Transform Rare Diseases™

At Agios, our vision is to redefine the future of rare disease treatment. Fueled by connections, we build trusted partnerships with communities – collaborating to develop and deliver innovative medicines that have the potential to transform lives. With a foundation in hematology, we combine biological expertise with real-world insights to advance a growing pipeline of rare disease medicines that reflect the priorities of the people we serve. Agios is a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts. To learn more, visit www.agios.com and follow us on LinkedIn and X.

Available Information about Agios

To achieve broad dissemination, Agios may disclose information to the public through a variety of disclosure channels including press releases, SEC filings, and public conference calls and webcasts. Some of the information distributed through these disclosure channels may be considered material information. Investors and others should note that Agios plans to use its website (www.agios.com) as a distribution channel to announce and give notice of Agios’ upcoming events and presentations (including, but not limited to, presentations at medical or healthcare conferences). Such information, which may be deemed material, will be available on the Investors section of the company’s website under the “Events & Presentations” tab. In addition, you may sign up to automatically receive email alerts about Agios’ upcoming events and presentations (“Calendar Alerts”) by visiting the “Email Alerts” option under the “IR Resources” tab of the Investors section of the company’s website and submitting your email address.

Contacts

Investor Contact
Morgan Sanford, Vice President, Investor Relations
Agios Pharmaceuticals
[email protected]

Media Contact

Eamonn Nolan, Senior Director, Corporate Communications
Agios Pharmaceuticals
[email protected]


Primary Logo

来源:Agios Pharmaceuticals|阿吉欧斯制药 · investor.agios.com